Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprenone vs PPIs for aGVHD Prevention Post-Transplantation
NCT07791849Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of teprenone in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of acute graft-versus-host disease at 100 days. Started Sep 2026; status: recruiting.
02
Drugs
teprenone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07791849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791849.